We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Dermatology |

In This Issue of JAMA Dermatology FREE

JAMA Dermatol. 2013;149(1):17. doi:10.1001/jamadermatol.2013.2196.
Text Size: A A A
Published online

The alkylating agent mechlorethamine hydrochloride has been used successfully in the treatment of the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) since the 1950s. Despite well-documented clinical experience with mechlorethamine, no topical formulation has been approved by the US Food and Drug Administration. Reliance on compounding pharmacies and the lack of insurance coverage have proven problematic. In this randomized, controlled, multicenter trial, Lessin et al demonstrate the safety and efficacy of a novel mechlorethamine, 0.02%, gel. A manufactured mechlorethamine, 0.02%, gel addresses the unmet needs for good manufacturing product quality assurance that will improve the availability of this drug for patients with MF-CTCL.

See Article

Skin cancer incidence has increased dramatically, and one of the main risk factors is exposure to UV radiation (UVR). Detailed population-based data about the prevalence of sunbed use and individual user characteristics are lacking. In this nationwide telephone survey of the general population in Germany, Schneider et al demonstrate that the prevalence of ever use of sunbeds was 39.2%. Higher prevalence rates were observed among female subjects, persons aged 18 to 25 years, and those with immigrant backgrounds, emphasizing the need for more frequent and higher quality educational interventions to change tanning behavior in these groups.

See Article

In the United States, approximately 500 000 patients are treated yearly for burn injuries, and the resulting scars have devastating emotional and physical impacts. Management has focused on addressing the aberrant collagen deposition seen in mature scars. Despite anecdotal reports that ablative lasers improve scars, no formal investigation has quantified improvement or explored underlying mechanisms. In this case series of 18 patients, Ozog et al demonstrate that fractional carbon dioxide laser treatment improved the appearance of mature burn scars and improved the collagen architecture. Given the excellent tolerability and lack of prolonged adverse effects, this technique should be further evaluated for the treatment of mature burn scars.

See Article

Bullous pemphigoid (BP) is an autoimmune bullous dermatosis in which autoantibodies to dermoepidermal junction components lead to subepidermal blister formation. Drug-induced BP has been documented in anecdotal case reports. In this case-control study comparing drug history of consecutive patients with BP, Lloyd-Lavery et al demonstrated that loop diuretics were used significantly more frequently by patients with BP. This association was independent of age, sex, cerebrovascular disease, dementia, hypertension, and ischemic heart disease. The mechanism behind such an association clearly warrants further investigation.

See Article

Calciphylaxis is a rare syndrome involving painful subcutaneous nodules and necrotic ulcerations of the skin that occurs in up to 4% of patients undergoing long-term dialysis. Restoration of blood flow is the most critical intervention. In this case series, el-Azhary et al describe 14 cases of calciphylaxis treated with tissue plasminogen activator (tPA), a thrombolytic agent that is an effective treatment for coagulopathic disorders of the skin microvasculature. Although tPA proved to be a useful adjuvant therapy for calciphylaxis, a multidisciplinary approach that includes wound care, debridement, thrombolytic therapy, restoration of tissue oxygenation, infection avoidance, and control of calcium-phosphate hemostasis is essential.

See Article

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.